文献速递消化系统肿瘤

食管癌与胃癌的EBV及错配修复缺陷状态差异:大型多中心研究

Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.
PubMed 文献 · Eur J Cancer · 2018-03-20

该多中心研究在988例食管癌和1213例胃癌中检测EBV编码RNA原位杂交与错配修复蛋白免疫组化,发现食管癌错配修复缺陷(0.8%)和MSI(0.6%)频率低且无EBER阳性,而胃癌错配修复缺陷为10.3%、EBER阳性为4.8%,提示EBV和错配修复缺陷在食管癌致癌中不发挥作用。

要点

  • 食管癌错配修复缺陷和MSI频率极低(0.8%和0.6%),无EBER阳性病例。
  • 胃癌错配修复缺陷频率为10.3%,EBER阳性为4.8%。
  • EBV阳性胃癌患者更年轻、男性更多且总生存更好。

核心结论

  • 这是迄今最大规模研究,表明EBV和错配修复缺陷在食管癌致癌中不发挥作用,与胃癌不同。
  • 通过检测错配修复缺陷/EBV状态筛选免疫治疗适宜患者的潜在临床价值在食管癌和胃癌间存在差异。

研究设计与样本

  • 多中心研究,在988例食管癌和1213例胃癌中采用EBER原位杂交检测EBV、免疫组化检测错配修复蛋白表达。
  • 在部分食管癌亚组中平行检测微卫星不稳定(MSI)与错配修复免疫组化。

主要发现

  • 食管癌错配修复缺陷频率为0.8%,MSI频率为0.6%,均低于胃癌的错配修复缺陷10.3%。
  • 食管癌无EBER阳性病例,胃癌EBER阳性率为4.8%。
  • EBV阳性胃癌患者更年轻(p=0.01)、男性更多(p=0.001)且总生存更好(p=0.012)。
  • 错配修复缺陷胃癌患者更年长(p=0.001)且更常见肠型组织学(p=0.022)。

临床怎么用

  • 胃癌患者可考虑检测错配修复缺陷和EBV状态以筛选免疫检查点抑制剂治疗潜在获益人群。
  • 食管癌患者中错配修复缺陷和EBV状态检测的临床筛选价值有限,不宜常规用于免疫治疗筛选。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oesophageal (OeC) and gastric (GC) cancer patients are treated with similar multimodal therapy and have poor survival. There remains an urgent clinical need to identify biomarkers to individualise patient management and improve outcomes. Therapy with immune checkpoint inhibitors has shown promising results in other cancers. Proposed biomarkers to predict potential response to immune checkpoint inhibitors include DNA mismatch repair (MMR) and/or Epstein-Barr virus (EBV) status. The aim of this study was to establish and compare EBV status and MMR status in large multi-centre series of OeC and GC. METHODS: EBV was assessed by EBV-encoded RNA (EBER) in situ hybridisation and MMR protein expression by immunohistochemistry (IHC) in 988 OeC and 1213 GC from multiple centres. In a subset of OeC, microsatellite instability (MSI) was tested in parallel with MMR IHC. RESULTS: Frequency of MMR deficiency (MMRdef) and MSI was low in OeC (0.8% and 0.6%, respectively) compared with GC (10.3%). None of the OeCs were EBER positive in contrast to 4.8% EBER positive GC. EBV positive GC patients were younger (p = 0.01), more often male (p = 0.001) and had a better overall survival (p = 0.012). MMRdef GC patients were older (p = 0.001) and showed more often intestinal-type histology (p = 0.022). CONCLUSIONS: This is the largest study to date indicating that EBV and MMRdef do not play a role in OeC carcinogenesis in contrast to GC. The potential clinical usefulness of determining MMRdef/EBV status to screen patients for eligibility for immune-targeting therapy differs between OeC and GC patients.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Hewitt LC, Inam IZ, Saito Y, et al. Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study. Eur J Cancer. 2018. PMID: 29550565. doi:10.1016/j.ejca.2018.02.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。